Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acrivastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrivastine SCHEMBL5053832 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL9051626 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL15392862 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL29414102 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL4702 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL11034921 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL2832062 | 0.99 | ADRA1A (0.98) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL9561912 | 0.98 | ADRA1A (0.96) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL9561915 | 0.98 | ADRA1A (0.96) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| SCHEMBL10505907 | 0.92 | SLC6A4 (0.84) | ADRA1AHRH1OPRK1SLC6A4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10570 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109705-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2026-04-23 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| EP-4691568-A2 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | Eye Therapies, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4691492-A2 | LIQUID COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4637713-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2025-10-29 | — | — | EP | claimed |
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4247331-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND | BIOPHARMA SYNERGIES S L (ES) | 2025-10-08 | — | — | EP | claimed |
| US-20250275951-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2025-09-04 | — | — | US | claimed |
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| EP-0316434-A1 | COUGH/COLD MIXTURES COMPRISING NON-SEDATING ANTIHISTAMINE DRUGS. | SUNSHINE ABRAHAM (US) | 1989-05-24 | — | — | EP | claimed |
| US-4829064-A | ACRIVASTINE, ASTEMIZOLE, AZATADINE, CETIRIZINE, KETOTIFIN, LORATIDINE | ANALGESIC ASSOCIATES (US) | 1989-05-09 | — | — | US | claimed |
| EP-0311677-A1 | COUGH/COLD MIXTURES COMPRISING NON-SEDATING ANTIHISTAMINE DRUGS. | SUNSHINE ABRAHAM (US) | 1989-04-19 | — | — | EP | claimed |
| WO-1988009656-A1 | COUGH/COLD MIXTURES COMPRISING NON-SEDATING ANTIHISTAMINE DRUGS | SUNSHINE ABRAHAM (US) | 1988-12-15 | — | — | WO | claimed |
| US-4783465-A | Cough/cold mixtures comprising non-sedating antihistamine drugs | ANALGESIC ASSOCIATES (US) | 1988-11-08 | — | — | US | claimed |
| WO-1988008302-A1 | COUGH/COLD MIXTURES COMPRISING NON-SEDATING ANTIHISTAMINE DRUGS | SUNSHINE ABRAHAM (US) | 1988-11-03 | — | — | WO | claimed |
| WO-1988007369-A1 | PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-06 | — | — | WO | claimed |
| EP-0284408-A1 | Pharmaceutical formulations of acrivastine | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-09-28 | — | — | EP | claimed |
| US-4650807-A | Antihistaminic compositions and methods containing pyridine derivatives | BURROUGHS WELLCOME CO. (US) | 1987-03-17 | — | — | US | claimed |
| US-4501893-A | ANTIHISTAMINE/CANT CONTAINS CARBOXYL GROUPS | MEDEVA CALIFORNIA, INC. | 1985-02-26 | — | — | US | claimed |